Xenter Secures $58.25 Million in Series B Funding

Xenter, a company based in Draper, Utah, known for its innovative approach to medical devices through Physical Intelligence technology, has successfully raised $58.25 million in a Series B funding round. Xenter's technology focuses on wirelessly transmitting real-time clinical data, aiming to improve outcomes in procedures related to heart attacks, strokes, and vascular issues.

Investment Details

The Series B funding round, which closed on June 30, 2026, saw participation from a variety of healthcare-focused investors, including family offices and existing shareholders. Although a lead investor was not specified, the group of investors is noted for sharing Xenter's vision of revolutionizing the way clinical data is captured and utilized across healthcare settings.

Strategic Use of Funds

The newly acquired funds are earmarked for several strategic initiatives:

  • Commercial Launch: A significant portion of the funding will be directed towards launching Xenter's diagnostics business.
  • Manufacturing Expansion: The company plans to increase its manufacturing capacity to meet anticipated demand.
  • Platform Development: Continued development of its wireless medical devices and AI-enabled healthcare intelligence platform is a priority.
  • Clinical Studies and Regulatory Programs: Support for clinical studies and regulatory programs will ensure the technologies meet necessary standards for broader commercial use.

Advancing the TechMed Platform

Xenter describes itself as a TechMed company, operating at the intersection of medical devices, healthcare data infrastructure, and clinical artificial intelligence. The company's platform is designed to connect medical devices, diagnostics, and digital health systems through a wireless ecosystem. This ecosystem, known as XenFi, centralizes what Xenter refers to as Physical Intelligence data—high-fidelity clinical, physiological, procedural, and diagnostic information generated during patient care.

The aim is to overcome the challenges of disconnected medical devices and fragmented information systems that currently hinder the integration of valuable data across a patient’s care journey. By capturing and organizing this data in real-time, Xenter seeks to support clinical decisions, enhance diagnostic accuracy, and aid in the development of future products and AI-powered analyses.

Looking Ahead

With this significant infusion of capital, Xenter is well-positioned to accelerate the commercialization of its integrated TechMed platform. As the platform's data library grows with each procedure, it holds the potential to help healthcare providers identify clinical patterns and improve patient outcomes. The expansion of Xenter’s capabilities marks a step forward in the seamless integration of medical technology and healthcare data systems.